Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Tom Luedde and Verena Keitel.
Tom Luedde
Connection Strength
1.053
Verena Keitel
  1. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021 Sep; 8:100164.
    View in: PubMed
    Score: 0.239
  2. Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature. Clin Case Rep. 2021 May; 9(5):e04068.
    View in: PubMed
    Score: 0.237
  3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021 May 17; 22(1):343.
    View in: PubMed
    Score: 0.236
  4. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure. Front Immunol. 2021; 12:645989.
    View in: PubMed
    Score: 0.236
  5. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction. Eur J Med Res. 2021 Aug 25; 26(1):98.
    View in: PubMed
    Score: 0.060
  6. Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. Cancer Cell. 2017 06 12; 31(6):771-789.e6.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.